Targeting Poxvirus Decapping Enzymes and mRNA Decay to Generate an Effective Oncolytic Virus

Area of Science:

• Virology
• Immunology
• Oncology

Background:

• Vaccinia virus (VACV) utilizes decapping enzymes D9 and D10 to degrade host mRNA, suppressing innate immune responses.
• VACV mutants deficient in D9 or D10 exhibit reduced virulence and impaired immune evasion.

Purpose of the Study:

• To investigate the oncolytic potential of VACV mutants lacking decapping enzymes D9 or D10.
• To evaluate the efficacy of these modified VACV strains against various tumor models.

Main Methods:

• Generation and characterization of D9- or D10-deficient VACV strains.
• Assessment of anti-tumor activity in syngeneic mouse tumor models and human hepatocellular carcinoma xenografts.
• Analysis of host anti-viral enzyme PKR activation by wild-type and mutant VACV.

Main Results:

• D9- or D10-deficient VACV demonstrated significant anti-tumor activity in multiple preclinical models.
• These VACV mutants effectively hyperactivated the host anti-viral enzyme PKR compared to wild-type VACV.
• The modified VACV strains retained essential viral replication genes while lacking a key immune evasion mechanism.

Conclusions:

• VACV mutants deficient in decapping enzymes D9 or D10 represent a promising new platform for oncolytic virotherapy.
• Targeting mRNA decay pathways offers a novel strategy for developing potent anti-cancer viral therapies.
• These VACV mutants overcome host defenses by hyperactivating PKR, leading to enhanced anti-tumor effects.